BiomX (PHGE)

• Market cap: $12.4M
• 1 day: -20.02%
• 5 days: 18.75%
• 1 month: 10.47%
• 3 months: -14.74%
• 6 months: -47.97%
• Year to date: -39.49%
• 1 year: -73.61%
• 5 years: -99.41%
• 10 years: -99.51%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Employees: 57

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

17% more funds holding

Funds holding: 18 [Q4 2024] → 21 (+3) [Q1 2025]

2% more capital invested

Capital invested by funds: $7.32M [Q4 2024] → $7.44M (+$128K) [Q1 2025]

1.73% less ownership

Funds ownership: 55.32% [Q4 2024] → 53.59% (-1.73%) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 3,058% upside
• Avg. target: $15 3,058% upside
• High target: $15 3,058% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis

3,058% upside $15

Buy Maintained

16 May 2025